Five critical blind spots limiting translational progress in primary sclerosing cholangitis
Year: 2026
Type: article
Abstract: Five critical blind spots limiting translational progress in primary sclerosing cholangitisPrimary sclerosing cholangitis (PSC) is a progressive inflammatory and fibrotic disease of the bile ducts that can lead to cirrhosis, liver failure, and cholangiocarcinoma (CCA).[1][2][3] Despite major advances in single-cell and spatial biology, multiomics, imaging, and international cohort development, PSC has not experienced a therapeutic revolution.I propose that this translational gap reflects critical deficiencies in human translational infrastructure: many of the most informative patients, tissues, and disease stages remain understudied.In this Editorial, I discuss 5 blind spots that continue to limit progress and propose strategies to overcome them through human-centered translational research.
Source: Hepatology Communications
Author: Martin Cornillet
Institution: Karolinska Institutet
Language: English
Topic: Liver Diseases and Immunity
Subfield: Hepatology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $2,700
OpenAlex ID: W7223144522